SANUWAVE Health (SNWV) Stock Price, News & Analysis

Company Overview

SANUWAVE Health, Inc. is a medical technology company specializing in non‐invasive regenerative shockwave therapy. The company’s core focus is the development and commercialization of Focused Shock Wave Therapy (FSWT) devices designed to accelerate tissue repair and provide pain relief for patients suffering from chronic wounds and musculoskeletal conditions. Utilizing patented acoustic wave technology, SANUWAVE’s platforms deliver pulsed acoustic energy to targeted areas, promoting neovascularization and tissue regeneration without the need for surgery.

The company’s flagship product, dermaPACE®, is engineered to treat chronic wound conditions such as diabetic foot ulcers and venous leg ulcers. dermaPACE® has received 510(k) clearance from the U.S. Food and Drug Administration and carries CE Mark approval for use in Europe. In addition to wound care, SANUWAVE offers orthoPACE®, which targets orthopedic injuries including plantar fasciitis and soft tissue tendinopathies. Both systems are designed for use in outpatient settings, wound care centers and specialty clinics, offering a non‐pharmacological option for patients unresponsive to standard therapies.

SANUWAVE Health maintains a global distribution network spanning North America, Europe, Asia and Latin America, partnering with medical device distributors, wound care specialists and healthcare institutions. The company continues to expand its market reach through strategic collaborations and clinical studies aimed at broadening the therapeutic applications of its FSWT technology. SANUWAVE also holds a growing intellectual property portfolio covering key aspects of its shockwave delivery platforms and treatment protocols.

Founded in the mid‐2000s and headquartered in Alpharetta, Georgia, SANUWAVE has evolved under the leadership of Dr. Gary S. Jenkins, who serves as Chief Executive Officer and President. Dr. Jenkins, a pioneer in acoustical wave research, has guided the company’s transition from R&D to commercial operations. SANUWAVE remains committed to advancing non‐invasive regenerative medicine solutions that improve patient outcomes and reduce healthcare costs.

Key Stats

• Today's Range: $33.58 to $37.52
• 50-Day Range: $26.24 to $36.02
• 52-Week Range: $5.17 to $39.50
• Volume: 122,554 shs
• Average Volume: 52,589 shs
• Market Capitalization: $308.19 million
• P/E Ratio: 4.33
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNWV Stock Analysis - Frequently Asked Questions

How have SNWV shares performed this year?

SANUWAVE Health's stock was trading at $23.00 at the start of the year. Since then, SNWV shares have increased by 56.6% and is now trading at $36.02.

How were SANUWAVE Health's earnings last quarter?

SANUWAVE Health, Inc. (OTCMKTS:SNWV) announced its quarterly earnings results on Monday, November, 16th. The company reported ($7.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.75) by $3.75. The business earned $1.97 million during the quarter. SANUWAVE Health had a negative net margin of 1.33% and a negative trailing twelve-month return on equity of 23.83%.

When did SANUWAVE Health's stock split?

Shares of SANUWAVE Health reverse split before market open on Friday, October 18th 2024.The 1-375 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of SANUWAVE Health?

Shares of SNWV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SANUWAVE Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SANUWAVE Health investors own include Co-Diagnostics (CODX), iBio (IBIO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 11/16/2020
• Today: 7/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:SNWV
• CIK: 1417663
• Web: www.sanuwave.com
• Phone: (770) 419-7525
• Fax: 770-419-8634
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.56)
• Trailing P/E Ratio: 4.33
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.81 million
• Net Margins: -1.33%
• Pretax Margin: -1.31%
• Return on Equity: -23.83%
• Return on Assets: -20.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $36.19 million
• Price / Sales: 8.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($14.02) per share
• Price / Book: -2.57

Miscellaneous

• Outstanding Shares: 8,556,000
• Free Float: 5,418,000
• Market Cap: $308.19 million
• Optionable: Not Optionable
• Beta: 1.24